

**Phase I Trial of a recombinant yeast-CEA vaccine (GI-6207)
in adults with metastatic CEA-expressing carcinoma**

Supplemental Table 1. Patient characteristics and dose assignments

Gender	
Male	10
Female	15
Median age (range)	52 (39–81)
Tumor types	
Colon cancer	20
Rectal cancer	2
Medullary thyroid, non-small cell lung, and pancreatic cancer	1 each
Median previous chemotherapy regimens	4 (1–6)
1 previous regimen	3
2 previous regimens	2
3–4 previous regimens	15
5–6 previous regimens	5
ECOG status	
ECOG 0	9
ECOG 1	16
Baseline CEA	
Median	107 ng/ml (5.7–10,982)
Patients with a CEA <20ng/ml	6
Patients with a CEA 20–100 ng/ml	5
Patients with a CEA 101–1,000 ng/ml	8
Patients with a CEA >1,000ng/ml	6
Patients enrolled at each dose level	
4 yeast units (YU)	4
16 yeast units (YU)	3
40 yeast units (YU)	18